TC Biopharm (Holdings) (TCBPY) AI Stock Analysis

• Market Cap: $127.54K
• Dividend Yield: N/A
• Average Volume (3M): 5.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,103,054
• 10 Day Avg. Volume: 3,222
• 30 Day Avg. Volume: 5,729
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

TC Biopharm's overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock's financial instability and operational inefficiencies are major concerns.

Positive Factors

Innovative Product Pipeline

TC Biopharm's focus on gamma-delta T cell technology positions it at the forefront of innovative cancer treatments, offering potential long-term growth through successful product development and commercialization.

Strategic Partnerships

Strategic partnerships with larger pharmaceutical firms provide TC Biopharm with financial support and market access, enhancing its ability to bring therapies to market and generate sustainable revenue.

Equity Improvement

Improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future financial stability and growth.

Negative Factors

Declining Revenues

A significant decline in revenue indicates challenges in product commercialization and market penetration, posing risks to long-term financial viability and growth prospects.

Negative Cash Flow

Persistent negative cash flow from operations suggests difficulties in sustaining business activities without external financing, impacting long-term operational sustainability.

High Debt Levels

High debt levels can strain financial resources, limiting flexibility and increasing risk, which could hinder the company's ability to invest in growth opportunities and weather economic downturns.

TC Biopharm (Holdings) Business Overview & Revenue Model

Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

How the Company Makes Money

TC Biopharm makes money primarily through the development and commercialization of its cell-based therapeutic products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop or distribute its therapies, thereby receiving upfront payments, milestone payments, and royalties on sales. Additionally, TC Biopharm may engage in research collaborations or receive grants and funding from governmental or non-governmental organizations to support its research and development activities. The success of its revenue model relies heavily on the successful advancement of its therapies through clinical trials and regulatory approval processes.

TC Biopharm (Holdings) Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

TC Biopharm (Holdings) Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCBPY, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.29, and below the 200-day MA of 2.67, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.54 is Neutral, neither overbought nor oversold. The STOCH value of 3.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCBPY.

TC Biopharm (Holdings) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.92B	-0.36	-43.38%	2.24%	22.38%	-2.16%
BDRX	45 Neutral	$396.48K	―	-60.37%	―	-100.00%	96.37%
GRI	45 Neutral	$4.55M	―	-248.95%	―	―	98.45%
TCBPY	38 Underperform	$127.54K	―		―	―	―
ONCO	33 Underperform	$4.84M	―	-254.09%	―	-9.34%	93.84%
SLRX	30 Underperform	$2.69M	―	-660.37%	―	―	74.27%
PCSA	29 Underperform	$9.66M	―	-212.38%	―	―	57.99%